[{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ferric Citrate","moa":"TfR1","graph1":"Hematology","graph2":"Phase III","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akebia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ferric Citrate","moa":"TfR1","graph1":"Hematology","graph2":"Phase IV","graph3":"Akebia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Akebia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Akebia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Averoa","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ferric Citrate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Averoa","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Averoa \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Averoa \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Ferric Citrate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : AVA1014 (ferric citrate coordination complex) is an iron containing phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis.

                          Brand Name : AVA1014

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 23, 2024

                          Lead Product(s) : Ferric Citrate

                          Therapeutic Area : Nephrology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The COMPASS trial was designed to investigate the efficacy and safety of dosing ferric citrate twice-daily as compared to the current U.S. FDA approved dosing of ferric citrate three times daily in adult patients with chronic kidney disease (CKD) not on ...

                          Brand Name : Auryxia

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 10, 2020

                          Lead Product(s) : Ferric Citrate

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase IV

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The NDA is based on JT and Torii's Phase 3 clinical study and other clinical studies in adult patients with IDA in Japan.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 18, 2020

                          Lead Product(s) : Ferric Citrate

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank